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To the editor: Heterogeneity amongst cohorts of patients treated for drug-resistant tuberculosis 
(DR-TB) make assessing the efficacy of new drugs and regimens unreliable without randomisation 
(1). We warmly welcome the randomised controlled trial (RCT) “Efficacy, safety and tolerability of 
linezolid for the treatment of XDR-TB: a study in China” presented by Tang et al. (2). Linezolid is now 
included on the WHO list of essential medicines (3) and falling prices will improve access. That Tang 
et al. report a 35.3% absolute reduction in the risk of a poor outcome by adding linezolid to an 
optimised background regimen argues in favour of wider use. Linezolid remains a WHO ‘Group 5’ 
drug, classifying it as an ‘anti-TB drug with limited data on efficacy and/or long term safety in the 
treatment of DR-TB’(4). The  limited data on the efficacy of drugs in this class has recently been 
reviewed (5).  These WHO classifications will shortly be reviewed and the exciting results from this 
study have the potential to alter guidance regarding the treatment of extensively drug-resistant 
tuberculosis (XDR-TB). We note the proposal to re-classify linezolid into Group 3 in an editorial in the 
October edition of the ERJ (6).  It is with this in mind that we seek some clarifications.   
  
The journal rightly requires that reports of randomised controlled trials conform to the CONSORT 
guidelines (7). We were therefore concerned to note that limited details were presented regarding 
the randomisation process and steps taken to ensure adequate allocation concealment. Details on 
the target sample-size calculation were also absent. The authors do not state whether the trial was 
registered in a clinical trial registry as per journal guidelines.  
 
A recent systematic review and meta-analysis by Zhang et al (8) highlighted Linezolid’s significant 
side-effect profile. The data presented by Tang and colleagues on rates of nausea and on the timing 
of myelosuppression and neuropathy will be of great interest to clinicians and patients.  The 
manuscript states: ‘Most adverse events resolved after reducing the dosage of linezolid or 
temporarily discontinuing linezolid, and only two patients were permanently discontinued from 
using the drug because of severe anaemia.’ Details of symptom severity and the number of patients 
left with cytopaenias or significant residual neuropathy would be hugely valuable.  
 
Figure 2 suggests that around a quarter of patients in the control group achieved sputum culture-
conversion in the first three months of the study, despite all having been sputum smear-positive for 
the preceding twelve months. This suggests that new agents other than linezolid were introduced in 
both arms at enrolment. It would be helpful to know whether other drugs that patients had not used 
previously were started when the patients were enrolled in the trial. In particular, many patients 
were reported to have been treated with clofazimine, an agent shown by the authors to be useful in 
the treatment of MDR-TB (9). It would also be relevant to know whether the background regimen 
was determined prior to randomisation; and whether there was any imbalance in newly-introduced 
drugs between the trial arms, both at enrolment and subsequently.  
 
Finally, early relapse following treatment is common (10).  Data on relapse-free survival from the 
other completed randomised controlled trial involving linezolid has been valuable in understanding 
the role of this drug(11).  Relapse-free survival is a more robust end-point and follow up for at least 
one year should be routine in randomised evaluations of TB treatment regimens. We hope this will 
be considered in future trial designs. 
 
If the authors could provide these additional details, it would greatly inform our understanding of 
the efficacy and place of linezolid in XDR regimens. This information would also be valuable to those 
who will shortly be drafting new international recommendations for DR-TB as well as to clinicians 
and programs providing XDR-TB care.  We congratulate the authors on an important study and look 
forward to their response. 
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